News Breaks |
|
|
| March 15, 2012 |
| 14:40 EDT |  | WPI, MYL, FRX, AVA | Mylan pulls out of talks to buy stake in Rottapharm, Reuters says
Mylan (MYL) has pulled out of discussions to buy a stake in Italian pharma firm Rottapharm after the selling family would not agree to give up control and would not compromise enough on price, according to sources reporting to Reuters. Rottapharm has also held talks with Watson Pharmaceuticals (WPI)and Forest Laboratories (FRX), but one of the sources said Watson was unlikely to be a buyer. Reference Link |
|
|
News For MYL;AVA;FRX;WPI From The Last 14 Days Check below for free stories on MYL;AVA;FRX;WPI the last two weeks. |
|
|
| May 23, 2013 |
| 08:10 EDT |  | FRX | Forest Labs says Howard Solomon to retire as CEO, President at year end
Forest Laboratories announced that Howard Solomon will retire as Chief Executive Officer and President, effective December 31, 2013. Subject to the same nominating and election processes annually as all directors, Solomon is expected to remain as Chairman through the 2014 Annual General Meeting, at which time another Chairman will be elected. Solomon will retain the title of Chairman Emeritus after the 2014 AGM and has agreed to serve as Senior Advisor to the Company following his retirement as CEO and President. As previously disclosed, an independent committee of Forest’s Board has been engaged in a succession planning process, including evaluating internal and external candidates. With Solomon’s retirement announcement, the Board has determined to bring the process to a close and expects to name a successor before the end of the year. The committee is being assisted by executive search firm Spencer Stuart, the company said. |
|
| 08:04 EDT | | FRX | Forest Labs says Howard Solomon to retire as CEO, President at year end
 Subscribe for More Information |
|
| May 22, 2013 |
| 11:53 EDT |  | MYL | High option volume stocks: UAN MYL ALNY SKS XIDE
Subscribe for More Information |
|
| May 21, 2013 |
| 07:35 EDT | | MYL | Mylan: Appellate Court rules in favor of company in patent infringement case
Subscribe for More Information |
|
| May 20, 2013 |
| 11:27 EDT | | MYL | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| 07:28 EDT |  | FRX | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| 07:27 EDT | | FRX | American Psychiatric Association to host annual meeting
Subscribe for More Information |
|
| May 17, 2013 |
| 14:48 EDT | | MYL | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | MYL | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 10:36 EDT | | FRX | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
| |
| 07:31 EDT | | MYL | Mylan launches generic Tricor tablets
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT | | MYL | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 17:36 EDT | | MYL | Paulson gives quarterly update on stakes
Subscribe for More Information |
|
| 11:42 EDT | | MYL | Mylan launches generic Zomig tablets
Subscribe for More Information |
|
| 07:03 EDT |  | MYL | Mylan highly unlikely to acquire Actavis, says Barclays
Subscribe for More Information |
|
| May 14, 2013 |
| 13:55 EDT | | MYL | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information |
|
| 13:22 EDT | | MYL | Actavis turned down $15B takeover bid from Mylan, Bloomberg reports
Subscribe for More Information |
|
| May 10, 2013 |
| 10:00 EDT |  | MYL, FRX | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
|
|
|
|
|
